Cellebrite DI (NASDAQ:CLBT – Free Report) had its price target raised by Deutsche Bank Aktiengesellschaft from $15.00 to $18.00 in a report published on Friday, Benzinga reports. The brokerage currently has a buy rating on the stock.
A number of other equities analysts have also weighed in on CLBT. Needham & Company LLC increased their price target on Cellebrite DI from $14.00 to $17.00 and gave the company a buy rating in a research report on Friday. Craig Hallum raised their target price on shares of Cellebrite DI from $16.00 to $20.00 and gave the stock a buy rating in a report on Friday. Lake Street Capital upped their price target on shares of Cellebrite DI from $13.50 to $17.00 and gave the company a buy rating in a research report on Friday. Bank of America raised their price objective on shares of Cellebrite DI from $13.00 to $17.00 and gave the stock a buy rating in a research note on Friday. Finally, JPMorgan Chase & Co. boosted their target price on shares of Cellebrite DI from $14.00 to $15.00 and gave the company an overweight rating in a research note on Wednesday, August 14th. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has a consensus rating of Buy and a consensus price target of $17.33.
Get Our Latest Report on Cellebrite DI
Cellebrite DI Price Performance
Cellebrite DI (NASDAQ:CLBT – Get Free Report) last posted its quarterly earnings results on Thursday, August 15th. The company reported $0.10 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.08 by $0.02. The company had revenue of $95.70 million for the quarter, compared to analysts’ expectations of $91.94 million. Cellebrite DI had a positive return on equity of 417.94% and a negative net margin of 32.57%. The firm’s revenue was up 24.8% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.05 earnings per share. On average, analysts anticipate that Cellebrite DI will post 0.34 earnings per share for the current year.
Institutional Investors Weigh In On Cellebrite DI
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Point72 Asia Singapore Pte. Ltd. increased its stake in shares of Cellebrite DI by 59.6% in the second quarter. Point72 Asia Singapore Pte. Ltd. now owns 2,724 shares of the company’s stock worth $33,000 after acquiring an additional 1,017 shares during the last quarter. Parallel Advisors LLC grew its stake in Cellebrite DI by 75.0% in the fourth quarter. Parallel Advisors LLC now owns 3,500 shares of the company’s stock valued at $30,000 after purchasing an additional 1,500 shares in the last quarter. Quarry LP purchased a new position in Cellebrite DI in the fourth quarter valued at about $36,000. Public Employees Retirement Association of Colorado acquired a new position in Cellebrite DI in the 2nd quarter worth about $71,000. Finally, nVerses Capital LLC purchased a new stake in shares of Cellebrite DI during the 2nd quarter worth about $103,000. Hedge funds and other institutional investors own 45.88% of the company’s stock.
Cellebrite DI Company Profile
Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.
Recommended Stories
- Five stocks we like better than Cellebrite DI
- How to Effectively Use the MarketBeat Ratings Screener
- Moderna Dips on Q2 Earnings But Can It Rip on a Short Squeeze?
- CD Calculator: Certificate of Deposit Calculator
- 2 Option Strategies to Maximize Profits in a Bear Market
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Lululemon Stock Gears Up for a Massive Comeback Rally
Receive News & Ratings for Cellebrite DI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellebrite DI and related companies with MarketBeat.com's FREE daily email newsletter.